Free Trial
LON:MPH

Mereo BioPharma Group plc (MPH.L) (MPH) Share Price, News & Analysis

Mereo BioPharma Group plc (MPH.L) logo

About Mereo BioPharma Group plc (MPH.L) Stock (LON:MPH)

Key Stats

Today's Range
N/A
50-Day Range
26.50
26.50
52-Week Range
N/A
Volume
49,264 shs
Average Volume
333,975 shs
Market Capitalization
£89.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter.

MPH Stock News Headlines

Mereo BioPharma Group plc
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Mereo BioPharma Group plc (MAH0.F)
Mereo BioPharma Group PLC ADR MREO
See More Headlines

MPH Stock Analysis - Frequently Asked Questions

Mereo BioPharma Group plc (MPH.L) (LON:MPH) released its quarterly earnings data on Tuesday, September, 29th. The company reported ($105.00) earnings per share for the quarter.

Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group plc (MPH.L) investors own include Bausch Health Companies (BHC), Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Bristol-Myers Squibb (BMY), Galaxy Digital (BRPHF) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
9/29/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
GBX 7.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£89.76 million
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (LON:MPH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners